Consolidated Statements of Operations and Comprehensive Loss - USD ($) |
12 Months Ended | ||||
|---|---|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|||
| Revenue | |||||
| Healthcare services income | $ 431,378 | $ 1,295,889 | |||
| Operating expenses | |||||
| Cost of healthcare services | (420,812) | (1,215,824) | |||
| Research and development expenses | (2,195,161) | (5,198,329) | (9,219,595) | ||
| General and administrative fees | (669,486) | (1,930,637) | (5,220,405) | ||
| Legal and professional fees | (803,285) | (2,538,161) | (2,888,140) | ||
| Other operating expenses | (272,609) | (1,067,690) | (261,038) | ||
| Total operating expenses | (3,940,541) | (11,155,629) | (18,805,002) | ||
| Other (expense) income, net | |||||
| Loss on investments in marketable securities, net | (9,266) | (134,134) | |||
| Unrealized gain from fair value change of the long-term investments, net | 6,431,088 | 6,108,872 | |||
| Impairment loss of long-term investment | (1,000,000) | (77,200) | (520,821) | ||
| Interest (expense) income, net | (146,924) | (121,145) | 146,588 | ||
| Gain on disposal of subsidiaries | 703 | ||||
| Government subsidies | 928,461 | 123,015 | 335,499 | ||
| Sundry income | 564 | 36,784 | 48,007 | ||
| Total other (expense) income, net | (217,196) | 6,383,276 | 5,984,011 | ||
| Net loss | (4,157,737) | (4,340,975) | (11,525,102) | ||
| Net (loss) income attributable to non-controlling interests | (110,069) | 1,516,328 | 1,725,542 | ||
| Net loss attributable to Aptorum Group Limited | $ (4,267,806) | $ (2,824,647) | $ (9,799,560) | ||
| Net loss per share attributable to Aptorum Group Limited | |||||
| - Basic (in Dollars per share) | [1] | $ (0.78) | $ (0.62) | $ (2.75) | |
| - Diluted (in Dollars per share) | [1] | $ (0.78) | $ (0.62) | $ (2.75) | |
| Weighted-average shares outstanding | |||||
| - Basic (in Shares) | [1] | 5,453,103 | 4,521,133 | 3,569,484 | |
| - Diluted (in Shares) | [1] | 5,453,103 | 4,521,133 | 3,569,484 | |
| Net loss | $ (4,157,737) | $ (4,340,975) | $ (11,525,102) | ||
| Net (loss) income attributable to non-controlling interests | (110,069) | 1,516,328 | 1,725,542 | ||
| Other comprehensive income (loss) | |||||
| Exchange differences on translation of foreign operations | 99,785 | (44,430) | 35,826 | ||
| Other comprehensive income (loss) | 99,785 | (44,430) | 35,826 | ||
| Comprehensive loss | (4,057,952) | (4,385,405) | (11,489,276) | ||
| Comprehensive (loss) income attributable to non-controlling interests | (110,069) | 1,516,328 | 1,725,542 | ||
| Comprehensive loss attributable to the shareholders of Aptorum Group Limited | $ (4,168,021) | $ (2,869,077) | $ (9,763,734) | ||
| |||||
| X | ||||||||||
- Definition Represent the amount of sundry income. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of realized and unrealized gain (loss) on investment. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in income from government assistance, classified as operating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as nonoperating. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in marketable security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of other comprehensive income (loss) attributable to parent entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|